PPARGC1A and melanoma: Inhibiting the mTORC pathway with AZD8055(or AZD2014) significantly reduced PGC1α levels and resensitized MEKi-resistant melanoma—which exhibited high OXPHOS—to MEKi treatment [50] (Fig. 1).